SMN1 and proximal spinal muscular atrophy: Risdiplam is a lifelong treatment and if the drug induces its own metabolism by increasing SMN protein expression, risdiplam dosage may have to be increased with longer duration of treatment to maintain clinical efficacy as children with SMA age and grow.